Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SERPINE1 short hairpin RNA is an experimental RNA interference (RNAi) therapeutic designed to silence the expression of the *SERPINE1* gene, which encodes Plasminogen Activator Inhibitor-1 (PAI-1). PAI-1 is a key regulator of the fibrinolytic system and is frequently overexpressed in various malignancies, where it contributes to tumor progression, cell proliferation, and metastasis. The shRNA molecule functions by binding to complementary sequences on the SERPINE1 mRNA, leading to its degradation and a subsequent reduction in PAI-1 protein levels. Research indicates that the effects of SERPINE1 knockdown are context-dependent; while it has been shown to inhibit growth and invasion in breast cancer and glioma models by modulating the ERK/p38 signaling axis, it may paradoxically promote proliferation in certain melanoma contexts through the modulation of p53/SMAD3 regulators.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SERPINE1 short hairpin RNA.